Altimmune Inc ALT:NASDAQ

Last Price$17.36NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change0(0.00%)
Bid (Size)$17.24 (2)
Ask (Size)$17.40 (1)
Day Low / HighN/A - N/A
Volume8.8 M
 

View Biotechnology IndustryPeer Comparison as of 08/12/2022

 

Altimmune Inc ( NASDAQ )

Price: $17.36
Change: +3.59 (26.07%)
Volume: 8.8 M
4:00PM ET 8/12/2022
 
 

Stoke Therapeutics Inc ( NASDAQ )

Price: $21.60
Change: +0.82 (3.95%)
Volume: 129.7 K
4:00PM ET 8/12/2022
 
 

Cassava Sciences Inc ( NASDAQ )

Price: $20.42
Change: +0.57 (2.87%)
Volume: 1.4 M
4:00PM ET 8/12/2022
 
 

Agenus Inc ( NASDAQ )

Price: $2.97
Change: +0.30 (11.24%)
Volume: 6.4 M
4:00PM ET 8/12/2022
 
 

Geron Corp ( NASDAQ )

Price: $2.35
Change: +0.30 (14.63%)
Volume: 5.0 M
4:00PM ET 8/12/2022
 

Read more news Recent News

--B. Riley Securities Raises Altimmune's Price Target to $26 from $21, Increases Likelihood of Technical, Regulatory Success; Keeps Buy Rating
9:13AM ET 8/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Altimmune Q2 Net Loss Narrows, Revenue Declines
8:01AM ET 8/11/2022 MT Newswires

Altimmune (ALT) reported a Q2 net loss Thursday of $0.42 per diluted share, narrowing from a $0.60 loss a year earlier. Analysts polled by Capital IQ...

Insider Sell: Altimmune
5:22PM ET 7/05/2022 MT Newswires

M Scot Roberts, Chief Scientific Officer, on July 01, 2022, sold 37,164 shares in Altimmune (ALT) for $445,968. Following the Form 4 filing with the SEC,...

Insider Sell: Altimmune
5:11PM ET 6/28/2022 MT Newswires

Diane Jorkasky, Director, on June 27, 2022, sold 17,610 shares in Altimmune (ALT) for $206,944. SEC Filing:...

Company Profile

Business DescriptionAltimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD. View company web site for more details
Address910 Clopper Road
Gaithersburg, Maryland 20878
Phone+1.240.654.1450
Number of Employees27
Recent SEC Filing08/12/20224
President, Chief Executive Officer & DirectorVipin K. Garg
Secretary, Chief Financial & Accounting OfficerRichard I. Eisenstadt
Chief Scientific OfficerM. Scot Roberts
Chief Technology OfficerBertrand Georges

Company Highlights

Price Open$13.80
Previous Close$13.77
52 Week Range$3.83 - 18.55
Market Capitalization$750.3 M
Shares Outstanding43.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.19
Beta vs. S&P 500N/A
Revenue$10.3 M
Net Profit Margin-2,789.38%
Return on Equity-49.22%

Analyst Ratings as of 03/21/2022

Buy
7
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset